What the research found

Researchers gave 40 night shift workers either 3 mg of melatonin or placebo daily for 4 weeks, taken roughly an hour before daytime sleep. They measured urinary levels of 8-OHdG, a biomarker that reflects oxidative DNA damage and repair activity.

During daytime sleep after night shifts, workers receiving melatonin showed 80% higher urinary 8-OHdG levels compared to placebo—suggesting their bodies were actively repairing oxidative DNA damage while sleeping. Interestingly, this signal disappeared during subsequent night shifts, when melatonin's effect wasn't observed.

The mechanism appears straightforward: night shift work suppresses natural melatonin production, which may impair the body's ability to coordinate repair processes during sleep. Supplemental melatonin may partially restore this signaling during daytime recovery.

Why it matters for you

If you're tracking biomarkers or managing a protocol that includes night shift work—whether that's rotating schedules or sustained overnight hours—this touches on a genuine biological liability. Circadian misalignment doesn't just affect sleep quality; it can suppress DNA repair capacity, which may accumulate risk over months and years.

The practical implication: if you work night shifts consistently and are concerned about long-term health, melatonin supplementation (at the dose tested here: 3 mg taken before daytime sleep) might help restore one specific repair pathway. It's not a complete fix for circadian disruption—light exposure, eating patterns, and timing of activity all matter too—but it addresses a real mechanism.

This is especially relevant if you monitor oxidative stress markers (like 8-OHdG if available through advanced testing) or track sleep architecture and recovery. It also contextualizes why night shift workers often report worse baseline biomarkers for inflammation and metabolic health.

Caveats

• Small, short study: 40 participants over 4 weeks is underpowered to detect long-term effects or individual variability
• Biomarker only: The study measured DNA repair signaling, not actual cancer outcomes or cumulative health impact
• Participant skew: Most worked in healthcare; results may not generalize to other night shift occupations
• Limited mechanistic detail: The effect was seen only during daytime sleep, not night shifts—timing and dose optimization remain unclear
• Uncontrolled variables: Natural light exposure wasn't measured or controlled, which directly affects endogenous melatonin and confounds interpretation
• No dose-response data: Only one dose (3 mg) was tested; optimal supplementation strategy is unknown